EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie

One‐Year Outcomes of Novel Transcatheter Edge‐to‐Edge Mitral Repair System in Patients With Functional Mitral Regurgitation

Kai Xu, Da Zhu, Hong Jiang iD, Jing Chen, Shaoliang Chen, Junjie Zhang iD, Ben He, Yan Wang, Guosheng Fu, Jiyan Chen, Jian An, Jiancheng Xiu und 10 weitere

Catheterization and Cardiovascular Interventions · 2025

DOI: 10.1002/ccd.70230 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Catheterization and Cardiovascular Interventions, 2025. Verfasst von Kai Xu und 21 weiteren Autor:innen. Beteiligte Einrichtung: General Hospital of Northern Theater Command, Shenyang, Liaoning, China. Hauptthemen laut MEDLINE: Mitral Valve Insufficiency, Mitral Valve, Cardiac Catheterization, Heart Valve Prosthesis Implantation. Die Arbeit nennt 20 Literaturangaben. Gefördert von: This study was supported by the National Key Project of Research and Development Plan during the Fourteenth Five-Year Plan Period (2022YFC2503400), Major Scien….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Transcatheter edge‐to‐edge repair (TEER) improves outcomes in patients with heart failure and moderate‐to‐severe functional mitral regurgitation (FMR) who remain symptomatic despite the use of maximal doses of guideline‐directed medical therapy (GDMT). The SQ‐Kyrin‐M system is a novel TEER device designed for FMR treatment.

Aims

This multicenter, prospective, single‐arm study (ClinicalTrials.gov number: NCT05988450) evaluates the safety and efficacy of the SQ‐Kyrin‐M system in severe symptomatic FMR.

Methods

A total of 125 eligible patients (mean age 65.5 ± 8.1 years) with heart failure and moderate‐to‐severe or severe FMR who remained symptomatic despite the use of maximal doses of GDMT were involved in the analysis. The primary endpoint was the composite rate of all‐cause mortality and heart failure hospitalization at 1 year post‐intervention. Independent assessments were conducted by an echocardiography core laboratory (ECL) and a clinical events committee (CEC).

Results

At 1 year, the primary endpoint rate was 16.0% (20/125), and the composite major adverse event rate was 10.4%. Mitral regurgitation was reduced to ≤ 2+ in 94.2% of patients, with significant left ventricular reverse remodeling (LVEDV reduction: 33.8 ± 55.4 mL, p < 0.001). Patient‐reported outcomes improved significantly, with Kansas City Cardiomyopathy Questionnaire (KCCQ) scores increasing by 15.9 ± 18.8 points ( p < 0.001) and 6‐minute walk distance (6MWD) improving by 46.7 ± 90.7 m ( p < 0.001). The proportion of patients in New York Heart Association (NYHA) class I/II increased from 30.4% to 84.4% ( p < 0.001).

Conclusions

The SQ‐Kyrin‐M transcatheter mitral valve repair system bolsters the evidence supporting the safety and efficacy of TEER interventions for FMR patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mitral Valve InsufficiencyMitral ValveCardiac CatheterizationHeart Valve Prosthesis ImplantationHeart FailureHeart Valve ProsthesisHumansMaleFemaleAgedTreatment OutcomeProspective StudiesTime FactorsMiddle AgedRecovery of FunctionSeverity of Illness IndexProsthesis DesignVentricular Function, LeftRisk Factors

Stichwörter der Autor:innen

edge‐to‐edge repairheart failuremitral regurgitationtranscatheter mitral valve repair

Autor:innen und Institutionen

  • General Hospital of Northern Theater Command, Shenyang, Liaoning, China.
  • Fuwai Yunnan Cardiovascular Hospital, Kunming, Yunnan, China.
  • Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
  • Nanjing First Hospital, Nanjing, Jiangsu, China.
  • Shanghai Chest Hospital, Shanghai, China.
  • Xiamen Cardiovascular Hospital Xiamen University, Fujian, Xiamen, China.

ORCID-Profile: Hong Jiang, Junjie Zhang, Xiang Cheng, Yingxian Sun, Bo Yu

Förderung

  • This study was supported by the National Key Project of Research and Development Plan during the Fourteenth Five-Year Plan Period (2022YFC2503400), Major Scien…

Zitieren

APA

Xu, K., Zhu, D., Jiang, H., Chen, J., Chen, S., Zhang, J., He, B., Wang, Y., Fu, G., Chen, J., An, J., Xiu, J., Guo, X., Li, Y., Cheng, X., Li, P., Chen, Y., Zhou, S., Sun, Y., …, & Han, Y. (2025). One‐Year Outcomes of Novel Transcatheter Edge‐to‐Edge Mitral Repair System in Patients With Functional Mitral Regurgitation. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.70230

Vancouver

Xu K, Zhu D, Jiang H, Chen J, Chen S, Zhang J, et al. One‐Year Outcomes of Novel Transcatheter Edge‐to‐Edge Mitral Repair System in Patients With Functional Mitral Regurgitation. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.70230

BibTeX
@article{Xu2025,
  author = {Xu, Kai and Zhu, Da and Jiang, Hong and Chen, Jing and Chen, Shaoliang and Zhang, Junjie and He, Ben and Wang, Yan and Fu, Guosheng and Chen, Jiyan and An, Jian and Xiu, Jiancheng and Guo, Xiaogang and Li, Yue and Cheng, Xiang and Li, Ping and Chen, Yuguo and Zhou, Shenghua and Sun, Yingxian and Yu, Bo and Pan, Xiangbin and Han, Yaling},
  title = {One‐Year Outcomes of Novel Transcatheter Edge‐to‐Edge Mitral Repair System in Patients With Functional Mitral Regurgitation},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2025},
  doi = {10.1002/ccd.70230}
}
Kostenlos starten →